Rapid and efficient transfer of the T cell aging marker CD57 from glioblastoma stem cells to CAR T cells

Oncoscience

Volumn 2, Issue 5, 2015, Pages 476-482

  Zhu, Xuekai ^a,b   Niedermann, Gabriele ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cancer stem cells; CD57; Chimeric antigen receptor; Glioblastoma; Trogocytosis

Indexed keywords

EID: 84955299568     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.164     Document Type: Article

References (28)

1. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013; 3: 388-398.
2. Eshhar Z. From the Mouse Cage to Human Therapy: A Personal Perspective of the Emergence of T-bodies/Chimeric Antigen Receptor T Cells. Hum Gene Ther. 2014; 25: 773-778.
3. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014; 123: 2625-2635.
4. Yan K, Yang K, Rich JN. The evolving landscape of glioblastoma stem cells. Curr Opin Neurol. 2013; 26: 701-707.
5. Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D, Kunz-Schughart LA. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol. 2013; 229: 355-378.
6. Zhu X, Prasad S, Gaedicke S, Hettich M, Firat E, Niedermann G. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget. 2015; 6: 171-184.
7. Akbar AN, Henson SM. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat Rev Immunol. 2011; 11: 289-295.
8. Restifo NP, Gattinoni L. Lineage relationship of effector and memory T cells. Curr Opin Immunol. 2013; 25: 556-563.
9. Becker JC, Andersen MH, Schrama D, Thor Straten P. Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother. 2013; 62: 1137-1148.
10. John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013; 19: 5636-5646.
11. Hombach AA, Abken H. Young T Cells Age During a Redirected Anti-Tumor Attack: Chimeric Antigen Receptor-Provided Dual Costimulation is Half the Battle. Front Immunol. 2013; 4: 135.
12. Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology. 2011; 134: 17-32.
13. Focosi D, Bestagno M, Burrone O, Petrini M. CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol. 2010; 87: 107-116.
14. Wu RC, Liu S, Chacon JA, Wu S, Li Y, Sukhumalchandra P, Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizee G, Radvanyi LG. Detection and characterization of a novel subset of CD8(+)CD57(+) T cells in metastatic melanoma with an incompletely differentiated phenotype. Clin Cancer Res. 2012; 18: 2465-2477.
15. Schlitter AM, Dorneburg C, Barth TF, Wahl J, Schulte JH, Bruderlein S, Debatin KM, Beltinger C. CD57(high) neuroblastoma cells have aggressive attributes ex situ and an undifferentiated phenotype in patients. PLoS One. 2012; 7: e42025.
16. Wahl J, Bogatyreva L, Boukamp P, Rojewski M, van Valen F, Fiedler J, Hipp N, Debatin KM, Beltinger C. Ewing's sarcoma cells with CD57-associated increase of tumorigenicity and with neural crest-like differentiation capacity. Int J Cancer. 2010; 127: 1295-1307.
17. Joly E, Hudrisier D. What is trogocytosis and what is its purpose? Nat Immunol. 2003; 4: 815.
18. Davis DM. Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response. Nat Rev Immunol. 2007; 7: 238-243.
19. Vanherberghen B, Andersson K, Carlin LM, Nolte-'t Hoen EN, Williams GS, Hoglund P, Davis DM. Human and murine inhibitory natural killer cell receptors transfer from natural killer cells to target cells. Proc Natl Acad Sci U S A. 2004; 101: 16873-16878.
20. LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, Carosella ED. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood. 2007; 109: 2040-2048.
21. Bonaccorsi I, Morandi B, Antsiferova O, Costa G, Oliveri D, Conte R, Pezzino G, Vermiglio G, Anastasi GP, Navarra G, Munz C, Di Carlo E, Mingari MC, et al. Membrane transfer from tumor cells overcomes deficient phagocytic ability of plasmacytoid dendritic cells for the acquisition and presentation of tumor antigens. J Immunol. 2014; 192: 824-832.
22. Gaedicke S, Braun F, Prasad S, Machein M, Firat E, Hettich M, Gudihal R, Zhu X, Klingner K, Schuler J, Herold-Mende CC, Grosu AL, Behe M, et al. Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells. Proc Natl Acad Sci U S A. 2014; 111: E692-701.
23. Hudrisier D, Riond J, Mazarguil H, Gairin JE, Joly E. Cutting edge: CTLs rapidly capture membrane fragments from target cells in a TCR signaling-dependent manner. J Immunol. 2001; 166: 3645-3649.
24. Qi L, Huang Y-l, Kogiso M, Mao H, Baxter P, Su JMF, Perlaky L, Lau CC, Chintagumpala M, Li X-N. Abstract 1484: CD57 defines a novel maker of glioblastoma stem cells that have greater invasive potential than CD133+ tumor cells. Cancer Research. 2014; 74: 1484.
25. Bilzer T, Stavrou D, Dahme E, Keiditsch E, Burrig KF, Anzil AP, Wechsler W. Morphological, immunocytochemical and growth characteristics of three human glioblastomas established in vitro. Virchows Arch A Pathol Anat Histopathol. 1991; 418: 281-293.
26. Leong ASY, Cooper K, Leong FJWM. (2003). Manual of diagnostic antibodies for immunohistology: Cambridge University Press).
27. Thies A, Schachner M, Berger J, Moll I, Schulze HJ, Brunner G, Schumacher U. The developmentally regulated neural crest-associated glycotope HNK-1 predicts metastasis in cutaneous malignant melanoma. J Pathol. 2004; 203: 933-939.
28. Gershon TR, Oppenheimer O, Chin SS, Gerald WL. Temporally regulated neural crest transcription factors distinguish neuroectodermal tumors of varying malignancy and differentiation. Neoplasia. 2005; 7: 575-584.